Tilray (NASDAQ:TLRY) Shares Down 1.2% After Analyst Downgrade

Tilray Inc (NASDAQ:TLRY)’s stock price fell 1.2% during mid-day trading on Monday after Roth Mkm lowered their price target on the stock from $2.00 to $1.75. Roth Mkm currently has a neutral rating on the stock. Tilray traded as low as $1.57 and last traded at $1.61. 9,479,634 shares changed hands during trading, a decline of 62% from the average session volume of 25,246,178 shares. The stock had previously closed at $1.63.

Institutional Trading of Tilray

Several large investors have recently made changes to their positions in the company. HighPoint Advisor Group LLC purchased a new position in shares of Tilray in the 4th quarter worth approximately $43,000. Madrona Financial Services LLC bought a new stake in shares of Tilray in the 1st quarter worth approximately $124,000. SpiderRock Advisors LLC bought a new stake in shares of Tilray in the 1st quarter worth approximately $247,000. Private Advisor Group LLC raised its holdings in shares of Tilray by 7.3% in the 1st quarter. Private Advisor Group LLC now owns 175,845 shares of the company’s stock worth $434,000 after purchasing an additional 12,021 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tilray by 8.7% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,679,532 shares of the company’s stock worth $6,699,000 after purchasing an additional 213,834 shares during the period. 9.35% of the stock is currently owned by institutional investors and hedge funds.

Tilray Price Performance

The company has a current ratio of 2.27, a quick ratio of 1.42 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.32 billion, a P/E ratio of -5.81 and a beta of 2.13. The business’s fifty day moving average is $1.75 and its 200 day moving average is $1.85.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.01%. The company had revenue of $200.00 million for the quarter, compared to analysts’ expectations of $218.70 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. Tilray’s revenue was up 13.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Tilray Inc will post -0.16 EPS for the current year.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.